July #49 : The Power of One: Uganda - by Timothy Burton

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

The Power of One

The Power of One: Senegal

The Power of One: Uganda

The Power of One: Zimbabwe

The Power of One: Zambia

World Weary

South Africa's Moment of Truth

Back to the Roots

Chain Reactions: Medicine Woman

Chain Reactions: Poetic Justice

Chain Reactions: Ray of Hope

Chain Reactions: Reluctant Witness

Guest Editor's Letter

To the Editor

Bath Sides Now

Walk the Talk

Rubber Suit

Memo Demo

Dread Locked

PWAs vs. Y2K

Jail Break

Say What

Gender Agenda

Simon Nkoli


POZarazzi: Spring Sprung

License to Kill

Keep HOPE Alive

POZ Picks

Show & Tell

The Holistic Truth

Get Over It

Sugar on Top

Cheer to Adhere

Gene Pool

Cream Puff

The Protease Prison

Out in Africa

Where to Find It

Grandma’s Recipe

Grace Under Pressure

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

July 1999

The Power of One: Uganda

by Timothy Burton

Vaccine Trial or Error

The government of Uganda has responded to HIV in a relatively proactive way since the beginning, declaring a national campaign against AIDS in 1986, when the first cases were identified in the country's Rakai district. Since then, messages extolling condoms have taken over local billboards and radio announcements in this East African country, a campaign credited with reducing infection rates by 25 percent over the past decade. Last year, Ugandan HIV infections were estimated at 1.84 million, still a high 10 percent of the country's population.

Last February, the Ugandan government showed that it's still ahead of the curve by hosting the first AIDS vaccine trials on the continent. After years of wrangling, 40 volunteers are now participating in the first phase of U.S.-sponsored trials for the vaccine, Pasteur Merieux Connaught's vCP205.

Yet the trial design will do little to encourage other African nations to follow Uganda's lead. VCP205, a combo of three HIV genes and a weakened canarypox virus, is based upon HIV subtype B -- the type prevalent in Europe and the Americas. The vaccine, if it works, may only combat subtype B infection. With Ugandans likely to carry subtypes A or D, such a trial may are all too likely to miss the mark.

In their defense, scientists have said they'll examine ways that vCP205 may also protect against the strains that more commonly infect Ugandans. Donna Kabatesi, MD, director of the Kampala-based Traditional and Modern Health Practitioners Together Against AIDS, says that at least infrastructure and scientific training will come out of the trials. She adds, "Any additional information will add to the process."

Meanwhile, in April, Uganda joined with four neighboring countries to form the Great Lakes Initiative, a landmark joint program to do prevention along the nations' shared trade routes.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.